1、该刊只有国际刊号。

2、投稿方式：在线投稿。

3、官网网址（协办单位微信公众号信息）：

https://www.keaipublishing.com/en/journals/extracorporeal-life-support/

4、投稿网址：

https://www.editorialmanager.com/ecls/default2.aspx

5、官网邮箱：ecls.editorialoffice@gmail.com

6、出刊日期：官方暂未公布刊期信息。

7、协办单位微信公众号：体外生命支持分会ChELSA

8、官网信息：2026年12月31日前提交的稿件免除APC费用。

2026年6月17日星期三

邀稿启事 |《Extracorporeal Life Support》创刊号诚征佳作

【协办单位微信公众号信息】

体外生命支持分会ChELSA2026年2月27日

我们诚挚地邀请您，向《Extracorporeal Life Support》（ECLS）期刊投稿。本刊将于2026年首期正式出版，现面向全球学者、临床专家及科研工作者公开征集优秀稿件。

《Extracorporeal Life Support》（ECLS）是由科爱（KeAi Publishing）出版，融通医健期刊出版（北京）有限公司主办，并由中国心胸血管麻醉学会体外生命支持分会协办的高水平、国际化同行评议、开放获取期刊。ECLS期刊的创立旨在发表严谨、具有临床相关性且方法学可靠的研究。

在此，我们热情邀请您，将您在本领域的原创性研究、综述、共识、病例报道、评论或前瞻性观点等文章投稿至ECLS期刊。

ECLS接收的文章领域包括但不限于：

心肺与呼吸支持：体外膜肺氧合、体外循环、体外二氧化碳清除、临时机械循环支持、永久机械循环支持、心室辅助装置以及全人工心脏。

肾脏与肝脏支持：肾脏替代治疗、血液灌流、分子吸附再循环系统，生物人工或混合型肝支持系统。

神经支持与神经接口：多模态神经监测、脑灌注策略、体外神经保护方案，以及与生命支持和康复相关的脑机接口。

体外血液与免疫调控：成分分离技术、血浆置换、血液吸附、体外光化学疗法，以及靶向体外免疫治疗。

移植与器官替代：离体器官灌注与、围移植/移植后体外生命支持、生物工程/人工器官以及再生医学。

一体化与多器官平台：联合器官支持系统以及闭环监测与控制平台。

工程、数据科学与创新：器械设计、生物材料与生物相容性、传感器、人工智能与计算建模，以及转化研究。

伦理、政策与教育：临床指南、患者血液管理、医学伦理、培训与模拟以及与生命支持技术相关的卫生政策。

投稿事宜：

- 期刊网站：https://www.keaipublishing.com/en/journals/extracorporeal-life-support/

- 投稿系统：稿件请通过Elsevier Editorial System提交https://www.editorialmanager.com/ecls/default2.aspx

- 更多信息：请访问官网或联系编辑部。

联系方式：bozhiyuan@fuwai.com、ganjiaqi@fuwai.com

期待您的杰出贡献！

《Extracorporeal Life Support》编辑部 谨启

Guide for Authors

【官网信息】

About the journal

Journal announcements

Extracorporeal

Life Support (ECLS) is an international, peer-reviewed, open-access

journal published by Elsevier, managed by Rongtong Healthcare Journal

Publishing (Beijing) Co., Ltd., and supported by ChELSA (the

Extracorporeal Life Support Branch, Chinese Society of Cardiothoracic

and Vascular Anesthesiology). Dedicated to the rapidly evolving

interdisciplinary field of extracorporeal life and organ support, ECLS

aims to provide a high-level platform integrating basic medicine,

engineering innovation, and clinical translation, with a focus on

publishing methodologically rigorous, clinically relevant, and impactful

research.

Aims and scope

Extracorporeal

Life Support (ECLS) is an international, peer-reviewed, open-access

journal dedicated to advancing the science, engineering, and clinical

practice of extracorporeal and organ-support therapies. The journal

serves a multidisciplinary community of clinicians, scientists,

engineers, ethicists, and allied health professionals across critical

care, surgery, cardiology, pulmonology, nephrology, neurology,

transplantation medicine, and biomedical engineering.

Aims

ECLS

aims to publish rigorous, clinically relevant, and methodologically

sound research that advances the science, engineering, ethics, and

implementation of extracorporeal and organ‑support systems. The mission is to connect disciplines, standardize evidence, and promote equitable access to life‑support technologies worldwide.

Scope

The scope encompasses, but is not limited to:

Cardiopulmonary

& Respiratory Support: extracorporeal membrane oxygenation (ECMO;

VA/VV), cardiopulmonary bypass (CPB), extracorporeal carbon dioxide

removal (ECCO₂R), temporary mechanical circulatory support, permanent mechnical circulatory support， ventricular assist devices (VADs), and total artificial hearts.

Renal

& Hepatic Support: renal replacement therapies, hemoperfusion,

molecular adsorbent recirculating system (MARS), and bioartificial or

hybrid liver support.

Neurological

Support & Interfaces: multimodal neuromonitoring, cerebral

perfusion strategies, extracorporeal neuroprotective approaches, and

brain–computer interfaces (BCIs) relevant to life support and

rehabilitation.

Extracorporeal

Blood & Immune Modulation: apheresis, plasma exchange,

hemoadsorption, extracorporeal photopheresis, and targe ted

extracorporeal immunotherapies.

Transplantation & Organ Replacement: ex‑vivo organ perfusion and machine preservation, peri‑/post‑transplant ECLS, bioengineered/artificial organs, and regenerative interfaces.

Integrated & Multi‑Organ Platforms: combined organ‑support systems and closed‑loop monitoring and control.

Engineering,

Data Science & Innovation: device design, biomaterials and

biocompatibility, sensors and miniaturization, artificial intelligence

and computational modeling, and translational research bridging

laboratory discoveries with clinical application.

Systems,

Ethics, Policy & Education: clinical guidelines, patient blood

management, medical ethics (indications, futility, equity, consent),

training and simulation, implementation science, and health policy

related to life‑support technologies.

Article types

ECLS publishes the following article types (word counts exclude abstract, references, tables, and figures unless noted):

Article type

Requirements

Original Article

≤ 7,000 words; structured abstract ≤

350 words; up to 6 tables/figures combined; trial registration for

clinical studies; STROBE/CONSORT/PRISMA/ARRIVE/CARE checklists as

applicable.

Short Communication

≤ 2,000 words; ≤ 2 tables/figures; rapid communications of novel findings or devices.

Review Article

≤ 9,000 words; includes narrative reviews and comprehensive overviews of established topics.

Advances / Updates / State-of-the-Art Review

≤ 4,000 words; focused synthesis of new developments, trends, or translational advances in ECLS and organ support.

Systematic Review/Meta‑analysis

≤ 6,000 words; PRISMA checklist and flow diagram; registered protocol recommended.

Consensus/Guideline

No strict limit; follow AGREE II where applicable; include evidence- grading methodology (e.g., GRADE).

Case Report/Series

≤ 2,500 words; CARE checklist; must provide mechanistic or translational insight.

Perspective / Policy / Ethics

≤ 3,000 words; grounded in evidence and policy frameworks.

Trial Protocol / Registered Report

≤ 4,000 words; registration ID required; SPIRIT or registered‑report format.

Editorial

≤ 1,500 words; by invitation or linked to accepted content.

Commentary

≤ 1,500 words; expert opinion, contextual analysis, or response to published articles.

Letter to the Editor

≤ 1,000 words; concise commentary or discussion on recently published articles or emerging topics.

Peer review

This

journal follows a double anonymized review process. Your submission

will initially be assessed by our editors to determine suitability for

publication in this journal. If your submission is deemed suitable, it

will typically be sent to a minimum of two reviewers for an independent

expert assessment of the scientific quality. The decision as to whether

your article is accepted or rejected will be taken by our editors. This

decision is final.

Our editors are not involved in making decisions about papers which:

they have written themselves.

have been written by family members or colleagues.

relate to products or services in which they have an interest.

Any

such submissions will be subject to the journal's usual procedures and

peer review will be handled independently of the editor involved and

their research group.

All

manuscripts are reviewed by the editorial office. Any papers which fail

to meet the basic standards of the journal will be desk-rejected for

reasons like out of scope, ethical conflicts, high similarities, lack of

originality, flaws in research design or methods, etc. The editorial

office will reassign selected papers to the Editor-in-chief.

The

Editor-in-chief will invite multiple reviewers to review the paper or

assign an editorial board member to invite reviewers to review this

paper.

After

at least two reviewers give their reviews and comments, the

Editor-in-chief (or the assigned Editor) provides feedback to the

authors, based on reviewer comments and his own review comments.

When

the author submits the revised manuscript, the assigned editor and

Editor-in-chief will collaborate to make a final decision.

For

submissions from the Editor-in-Chief, Associate Editors, Guest

Editor(s), other journal Board members, and authors who have conflicts

of interest with them, we ensure that the paper is handled

confidentially by a different team member.

For

submissions to Special Issues; if there are conflicts of interest

between the Guest Editor(s) and authors, the submissions will be handled

by another Editor from the Editorial Board who will manage the peer

review process and make the decision whether to accept or reject the

paper after peer review.

Read more about peer review.

KeAi Guide for authors: Open Access

This

is an open access journal: all articles will be immediately and

permanently free for everyone to read and download. To provide open

access, this journal has an open access fee (also known as an article

publishing charge APC) which needs to be paid by the authors or on their

behalf e.g. by their research funder or institution. Permitted third

party (re)use is defined by the following Creative Commons user

licenses.

Creative Commons Attribution (CC BY)

Allows

users to: distribute and copy the article; create extracts, abstracts,

and other revised versions, adaptations or derivative works of or from

an article (such as a translation); include in a collective work (such

as an anthology); and text or data mine the article. These uses are

permitted even for commercial purposes, provided the user: gives

appropriate credit to the author(s) (with a link to the formal

publication through the relevant DOI); includes a link to the license;

indicates if changes were made; and does not represent the author(s) as

endorsing the adaptation of the article or modify the article in such a

way as to damage the authors' honor or reputation.

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Allows

users to: distribute and copy the article; and include in a collective

work (such as an anthology). These uses are permitted only for

non-commercial purposes, and provided the user: gives appropriate credit

to the author(s) (with a link to the formal publication through the

relevant DOI); provides a link to the license; and does not alter or

modify the article.

If

you need to comply with your funding body policy you can apply for a CC

BY license after your manuscript is accepted for publication.

Article Publishing Charge (APC)

As

an open access journal with no subscription charges, a fee (Article

Publishing Charge, APC) is payable by the authors, or their institution

or funders, to cover the costs associated with publication. This ensures

your article will be immediately and permanently free to access by

everyone.

The

open access publication fee for this journal is USD 1000, plus taxes.

All APCs for articles submitted to the journal before the

31-December-2026 will be fully waived.

......

更多详见：

https://www.keaipublishing.com/en/journals/extracorporeal-life-support/guide-for-authors/